Kayla McNiece, MD
MOHS-Micrographic Surgery · Bellaire, TXNPI 1205254943
Payments from drug & device makers
Across 574 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$1K
- Lilly USA, LLC$1K
- Sun Pharmaceutical Industries Inc.$723
- Arcutis Biotherapeutics, Inc.$666
- Regeneron Healthcare Solutions, Inc.$632
- plus $4K from 26 others
What the payments were for
- Food & beverage$13,068100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 220 | $4,424 |
| Johnson & Johnson | 58 | $1,318 |
| Lilly USA, LLC | 46 | $1,046 |
| Sun Pharmaceutical Industries Inc. | 29 | $723 |
| Arcutis Biotherapeutics, Inc. | 19 | $666 |
| Regeneron Healthcare Solutions, Inc. | 28 | $632 |
| Sanofi | 16 | $580 |
| UCB, Inc. | 10 | $445 |
| Amgen | 19 | $419 |
| Journey Medical Corporation | 5 | $355 |
| Galderma Laboratories, L.p. | 5 | $239 |
| Mayne Pharma Commercial LLC | 15 | $220 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 14 | $210 |
| Novartis | 13 | $189 |
| Bioventus LLC | 4 | $187 |
| Dermavant Sciences, Inc. | 16 | $185 |
| Organogenesis Inc. | 3 | $170 |
| Helsinn Therapeutics (U.S.), Inc. | 3 | $156 |
| VYNE Pharmaceuticals Inc. | 11 | $150 |
| Pfizer | 8 | $144 |
| Biofrontera Inc. | 6 | $121 |
| Almirall LLC | 5 | $85 |
| Organon | 5 | $72 |
| Misonix Inc | 1 | $55 |
| LEO Pharma Inc. | 3 | $54 |
| Boehringer Ingelheim | 2 | $51 |
| Incyte Corporation | 3 | $50 |
| Kerecis Limited | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Sandoz | 1 | $19 |
| Fidia Pharma USA Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,068 in reported general payments places this provider in the 90th percentile of 109 mohs-micrographic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $48,381 |
| Mupirocin | 434 | $3,121 |
| Fluorouracil | 29 | $1,814 |
| Imiquimod | 15 | $533 |
| Ketoconazole | 27 | $379 |
| Triamcinolone Acetonide | 23 | $374 |
| Hydrocortisone | 11 | $144 |
| Doxycycline Hyclate | 16 | $141 |
| Cephalexin | 30 | $137 |
| Tramadol Hcl | 28 | $61 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Bellaire
- Suneel ChilukuriBellaire$323K
- Jeffrey BubleyBellaire$4K
- Leonard GoldbergBellaire$4K
- Aaron FarbergRockwall$1.9M
- Ryan O QuinnSan Antonio$167K
- Paul FriedmanHouston$131K
- Brent SpencerFrisco$79K
- Katherine FialaTemple$34K
- Julie CroleyThe Woodlands$30K
- Hubert ChodkiewiczCedar Park$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.